Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: Riding high with stem cells

> Cycling season is in full gear and for the rapidly growing number of enthusiasts, it means many miles on tarmac and trail, Strava leaderboard competitions and various degrees of obsession with the world’s major races. I’m not much of a road rider...

Right Turn: A new way to meat your favourite celebrity

> CCRM’s intrepid communications summer student is back! Erin Sugar gets right to the meat of the issue in today’s Right Turn. Does it leave you hungry for more or salivating with anger? Sometimes, an ordinary encasement of all-beef or pork salami is just not going...

Right Turn: Expose yourself (or your work)

> Looking for something to do this weekend? Got something to say or show about stem cells? How about one of following — each of them gives you an opportunity to win and/or gain exposure: Write an essay on “Why I want to go to ISSCR 2014”. Fellow...

Update from the Clinic: April

. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...

Data is king

> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are...

Regenerative Medicine Deal Review: April

. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!